Prevalence of Hepatitis B, Hepatitis C, and HIV in Multiply Transfused Sickle Cell Disease Patients from Oman.
HBV
HCV
HIV
Hepatitis
Infection
Prevalence
Journal
Mediterranean journal of hematology and infectious diseases
ISSN: 2035-3006
Titre abrégé: Mediterr J Hematol Infect Dis
Pays: Italy
ID NLM: 101530512
Informations de publication
Date de publication:
2019
2019
Historique:
received:
29
07
2019
accepted:
24
09
2019
entrez:
9
11
2019
pubmed:
9
11
2019
medline:
9
11
2019
Statut:
epublish
Résumé
In Oman, the prevalence of hepatitis B (HBV) infection is 5.8%, with 2.8-7.1% HBV carriers. Hepatitis C (HCV) prevalence among Omanis is 0.41%. A total of 2917 human immunodeficiency virus (HIV) infections were notified among Omanis by 2017. This study was performed as there was no data on the prevalence of HIV, HBV and HCV in sickle cell disease (SCD) patients from Oman. In this retrospective, cross-sectional study, medical records of all SCD patients who attended our hospital between 2011 to 2017 were retrieved from the hospital information system. Following approval by the local medical research and ethics committee, data on HIV, HBV, and HCV exposure were recorded to estimate the prevalence. Among a total of 1000 SCD patients (491 males and 509 females), twenty-three (2.3%) patients showed positive serology for hepatitis B surface antigen (HbsAg), of whom sixteen (1.6%) were HBV DNA positive. 126 (12.6%) had anti-HCV antibodies (anti-HCV), of whom fifty-two (5.2%) were HCV RNA positive. None of the patients had positive serology for HIV. A normal liver was observed on abdominal ultrasound in 788 (78.8%) patients, whereas 208 (20.8%) had hepatomegaly, and 4 (0.4%) had liver cirrhosis. Thirty-six (3.6%) patients died, but in only two patients, the mortality was due to cirrhosis of liver. This study provides the first comprehensive data on the prevalence of HBV and HCV infections among Omani SCD patients exposed to blood transfusions. Reassuringly, no case with HIV was observed.
Sections du résumé
BACKGROUND
BACKGROUND
In Oman, the prevalence of hepatitis B (HBV) infection is 5.8%, with 2.8-7.1% HBV carriers. Hepatitis C (HCV) prevalence among Omanis is 0.41%. A total of 2917 human immunodeficiency virus (HIV) infections were notified among Omanis by 2017. This study was performed as there was no data on the prevalence of HIV, HBV and HCV in sickle cell disease (SCD) patients from Oman.
STUDY DESIGN AND METHODS
METHODS
In this retrospective, cross-sectional study, medical records of all SCD patients who attended our hospital between 2011 to 2017 were retrieved from the hospital information system. Following approval by the local medical research and ethics committee, data on HIV, HBV, and HCV exposure were recorded to estimate the prevalence.
RESULTS
RESULTS
Among a total of 1000 SCD patients (491 males and 509 females), twenty-three (2.3%) patients showed positive serology for hepatitis B surface antigen (HbsAg), of whom sixteen (1.6%) were HBV DNA positive. 126 (12.6%) had anti-HCV antibodies (anti-HCV), of whom fifty-two (5.2%) were HCV RNA positive. None of the patients had positive serology for HIV. A normal liver was observed on abdominal ultrasound in 788 (78.8%) patients, whereas 208 (20.8%) had hepatomegaly, and 4 (0.4%) had liver cirrhosis. Thirty-six (3.6%) patients died, but in only two patients, the mortality was due to cirrhosis of liver.
CONCLUSIONS
CONCLUSIONS
This study provides the first comprehensive data on the prevalence of HBV and HCV infections among Omani SCD patients exposed to blood transfusions. Reassuringly, no case with HIV was observed.
Identifiants
pubmed: 31700583
doi: 10.4084/MJHID.2019.058
pii: mjhid-11-1-e2019058
pmc: PMC6827606
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e2019058Déclaration de conflit d'intérêts
Competing interests: The authors declare no conflict of Interest.
Références
N Engl J Med. 2000 Jun 22;342(25):1855-65
pubmed: 10861320
Transfus Med Rev. 2007 Apr;21(2):118-33
pubmed: 17397762
Sex Transm Infect. 2012 Nov;88(7):533
pubmed: 22717473
N Engl J Med. 1992 Aug 6;327(6):369-73
pubmed: 1320736
World J Gastroenterol. 2014 Sep 7;20(33):11595-617
pubmed: 25206267
Pediatr Allergy Immunol Pulmonol. 2017 Dec 1;30(4):191-201
pubmed: 29279787
Best Pract Res Clin Gastroenterol. 2008;22(6):991-1008
pubmed: 19187863
Arch Med Res. 2006 Oct;37(7):895-8
pubmed: 16971232
Ann Trop Paediatr. 1995 Jun;15(2):121-8
pubmed: 7677412
Int J Infect Dis. 2016 May;46:116-25
pubmed: 26996460
Sultan Qaboos Univ Med J. 2015 Feb;15(1):e46-51
pubmed: 25685385
Open Virol J. 2018 Feb 28;12:16-25
pubmed: 29541275
N Engl J Med. 1997 Sep 11;337(11):762-9
pubmed: 9287233
Ann Intern Med. 1996 Oct 15;125(8):634-9
pubmed: 8849147
J Hepatol. 1999;31 Suppl 1:17-24
pubmed: 10622555
Transfusion. 2005 May;45(5):807-13
pubmed: 15847673
PLoS One. 2014 May 16;9(5):e97759
pubmed: 24835494
Sultan Qaboos Univ Med J. 2018 Feb;18(1):e3-e12
pubmed: 29666675
ScientificWorldJournal. 2009 Jan 18;9:46-67
pubmed: 19151898
J Pediatr Gastroenterol Nutr. 1999 Jul;29(1):101-3
pubmed: 10400115
J Infect. 2006 Mar;52(3):202-6
pubmed: 16271396
Infection. 1993 May-Jun;21(3):164-7
pubmed: 7690010
Sex Transm Infect. 2012 Nov;88(7):528-33
pubmed: 22628662
Mediterr J Hematol Infect Dis. 2016 Sep 01;8(1):e2016046
pubmed: 27648209
BMC Infect Dis. 2017 Nov 1;17(Suppl 1):703
pubmed: 29143613
J Trop Pediatr. 2003 Jul;49 Suppl 1:i1-20
pubmed: 12934793
East Mediterr Health J. 2001 Nov;7(6):1004-11
pubmed: 15332742
Gastroenterol Hepatol (N Y). 2015 Jul;11(7):458-66
pubmed: 27118941
Mediterr J Hematol Infect Dis. 2016 Jan 01;8(1):e2016007
pubmed: 26740868
Lancet. 2010 Dec 11;376(9757):2018-31
pubmed: 21131035
Semin Liver Dis. 2000;20(1):17-35
pubmed: 10895429
Hemoglobin. 2010 Jan;34(2):135-44
pubmed: 20353348
Int J Infect Dis. 2018 Jun;71:94-99
pubmed: 29783175
Gut Pathog. 2018 Mar 5;10:9
pubmed: 29515657
J Sci Res Med Sci. 2003 Aug;5(1-2):15-20
pubmed: 24019730
Transfusion. 2009 Oct;49(10):2200-7
pubmed: 19538543